Dr. Habte A. Yimer, MD | TYLER, TX ...

Dr. Habte A Yimer

Claim this profile

Texas Oncology - Tyler

Studies Multiple Myeloma
Studies Non-Hodgkin's Lymphoma
19 reported clinical trials
33 drugs studied

Area of expertise

1

Multiple Myeloma

Habte A Yimer has run 5 trials for Multiple Myeloma.

2

Non-Hodgkin's Lymphoma

Habte A Yimer has run 4 trials for Non-Hodgkin's Lymphoma. Some of their research focus areas include:

EZH2 positive
CNG positive
CNG negative

Affiliated Hospitals

Image of trial facility.

Texas Oncology - Tyler

Image of trial facility.

(USO) Texas Oncology (Tyler)

Clinical Trials Habte A Yimer is currently running

Image of trial facility.

GM T Cell Therapy Long-Term Follow-Up

for Cancer

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Recruiting

1 award

Phase 2 & 3

Image of trial facility.

Cema-cel

for B-Cell Lymphoma

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.

Recruiting

1 award

Phase 2

5 criteria

More about Habte A Yimer

Clinical Trial Related

7 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Habte A Yimer has experience with

  • Rituximab
  • Lenalidomide
  • Selinexor
  • Tazemetostat
  • Dexamethasone
  • TAK-981

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Habte A Yimer specialize in?

Is Habte A Yimer currently recruiting for clinical trials?

Are there any treatments that Habte A Yimer has studied deeply?

What is the best way to schedule an appointment with Habte A Yimer?

What is the office address of Habte A Yimer?

Is there any support for travel costs?